Last Updated: June 27, 2026

Suppliers and packagers for VYFEMLA


✉ Email this page to a colleague

« Back to Dashboard


VYFEMLA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Lupin VYFEMLA ethinyl estradiol; norethindrone TABLET;ORAL-28 201886 ANDA Lupin Pharmaceuticals, Inc. 68180-875-73 3 POUCH in 1 CARTON (68180-875-73) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK * 21 TABLET in 1 BLISTER PACK (68180-495-74) * 7 TABLET in 1 BLISTER PACK (68180-500-74) 2020-11-04
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for VYFEMLA

Last updated: June 9, 2026

VYFEMLA Suppliers: Who Manufactures and Supplies Vyfemla (Levonorgestrel/Ethinyl Estradiol) for Distribution?

Vyfemla is a branded combined oral contraceptive (COC) product containing ethinyl estradiol and levonorgestrel. The supplier landscape typically splits into (1) manufacturing and packaging of the finished drug product, (2) sourcing of active pharmaceutical ingredients (APIs), and (3) distribution of finished product into the US via wholesale and specialty channels.

No complete, reliable supplier mapping (API vendor + CDMO/finished-dose manufacturer + FDA-listed labeler + current distributors/wholesalers) can be produced from the information provided in this request.

What companies supply the API for Vyfemla (levonorgestrel/ethinyl estradiol)?

A credible API supplier list requires confirmation of:

  • the labeled API “manufacturer”/“supplier” details (often reflected in filings and/or DMF cross-references), and
  • the Orange Book and/or FDA labeling “manufactured for” and “distributed by” entries tied to the specific Vyfemla NDC strengths.

Those specifics are not included in the request, so an accurate API vendor roster cannot be stated.

Which levonorgestrel API suppliers feed US COCs?

Many suppliers serve levonorgestrel and ethinyl estradiol markets globally, but supplier attribution to Vyfemla specifically requires direct linkage to the product’s NDC and FDA submissions.

Which ethinyl estradiol API suppliers feed US COCs?

Same issue: generic industry vendor lists exist, but Vyfemla-specific assignments must be traced to the NDC’s manufacturer and drug-substance section in regulatory records.

Who manufactures and packages Vyfemla finished tablets in the US?

Finished-dose “supplier” is normally identified by:

  • the FDA labeler/“manufactured for” and “distributed by” language,
  • the NDC labeler entry, and
  • the manufacturing site(s) listed in Orange Book or labeling for the specific strength and dosage form.

Those NDC-level details are not provided, so finished-dose manufacturers and packagers cannot be verified.

Which CDMOs commonly produce levonorgestrel/ethinyl estradiol tablets?

A number of CDMOs produce generic and branded COCs. Assigning any of them to Vyfemla requires confirmed labeler/manufacturing-site attribution.

What packaging suppliers support Vyfemla blistering or bottle packaging?

Packaging vendors for tablet COCs are downstream suppliers. A product-specific packaging chain cannot be stated without NDC labeling and manufacturing-site documentation.

What does the Orange Book list as the manufacturer for Vyfemla?

Orange Book entries can identify the “Applicant/Holder” and the listed manufacturers for each NDC. To answer this precisely, the Vyfemla NDC(s) must be known.

No NDC is included in the request, so Orange Book status and listing details cannot be reported.

What are Vyfemla distributors and wholesale channel suppliers in the US?

Distribution suppliers usually appear as:

  • “distributed by” label language,
  • registered distributors on wholesaler purchase ledgers,
  • and in some cases, specialty distributor arrangements.

Those details are not provided here, so a verified distribution supplier list cannot be generated.

How does Vyfemla’s supply chain compare with other levonorgestrel/ethinyl estradiol generics?

Comparisons require:

  • same-dose comparators (same regime and formulation),
  • matched NDCs across products, and
  • manufacturer-site and labeler crosswalk.

The request provides no comparator list or Vyfemla NDCs.

What generic entry risks exist for Vyfemla supply continuity?

Supply continuity risk depends on:

  • patent/exclusivity status,
  • manufacturing scale dependency on specific sites,
  • and reliance on sole API or single-site finished-dose supply.

No exclusivity/patent timeline or manufacturing/site details are included, so risk cannot be quantified.

Key Takeaways

  • A Vyfemla supplier map (API suppliers, finished-dose manufacturers/CDMOs, packaging suppliers, and US distributors) cannot be provided from the information supplied.
  • Supplier identification for Vyfemla requires product-specific NDC-level and FDA labeling/regulatory linkages that are not present in the request.

FAQs

  1. How do I find the exact API supplier for a specific Vyfemla NDC?
  2. Which finished-dose manufacturers are listed for Vyfemla in FDA labeling?
  3. What does Orange Book “Applicant” mean for Vyfemla and its generic manufacturers?
  4. How can manufacturing-site changes affect Vyfemla supply availability?
  5. Where do I verify Vyfemla distribution partners for US wholesalers?

References

No sources were cited because no verified Vyfemla NDC, Orange Book entry, labeling page, or FDA submission details were provided in the request.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.